Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.
The US District Court for the District of New Jersey also ruled that generic drugs makers Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals, Torrent Pharma, Mylan Pharmaceuticals and Mylan have all infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
8 of the best riverside properties for saleThe best riverside properties for sale – from a Grade II-listed former mill house with views over the River Chelmer in Essex, to a townhouse on a Georgian terrace overlooking the Avon Gorge in Clifton, Bristol
-
Will “Liberation Day” strike again?Donald Trump’s 90-day tariff pause comes to an end on 9 July. Can we expect further market turmoil?
